Patent · US Active

Optimized anti-CD20 monoclonal antibodies having Fc variants

US8084582B2 · kind B2 · utility

76Cited by

46References

8Claims

0Family size

Assignee

Xencor, Inc. · US

Inventors

Bassil Dahiyat · Altadena, US
Gregory Alan Lazar · Los Angeles, US
Omid Vafa · Monrovia, US

Key dates

Filing date	Jun 30, 2005
Grant date	Dec 27, 2011
Priority date	—
Expiry date	Aug 17, 2029

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to optimized CD20 antibodies having Fc variants, methods for their generation, and method for their application, such as methods of enhancing macrophage activation, particularly for therapeutic purposes.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.